Nordic Nanovector ASA (DE:8NN) has released an update.
Thor Medical ASA has released new investor materials outlining their progress on a fast-track plan to deliver commercial volumes of Th-228, a valuable isotope for cancer treatment, by the end of 2025, anticipating a market growth up to USD 1 billion by 2032. The company is currently constructing a pilot plant to validate their production technology and respond to the increasing demand from radiopharmacological companies in clinical trials. Thor Medical’s innovative production process for alpha-emitters doesn’t require irradiation or nuclear reactors, positioning them as an emerging, environmentally friendly supplier in the radiopharmaceutical industry.
For further insights into DE:8NN stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
